Stem Cell Clinic

Hemostemix Announces the Appointment of Dr. Ronnie Hershman to the Board of Directors and Provides a Corporate Update – BioSpace

By adminFebruary 11, 2020Stem Cell Medical Center

CALGARY, Alberta, Feb. 10, 2020 (GLOBE NEWSWIRE) --Hemostemix. (Hemostemix or the Company) (TSXV: HEM; OTC: HMTXF) is pleased to announce the appointment of Dr. Ronnie Hershman, M.D., F.C.C.S., to its Board of Directors. Dr. Hershman is a successful, practicing cardiologist with over three decades of experience. Dr. Hershman graduated Magna Cum Laude from the Sophie Davis Center for Biomedical Research in 1980 and received his medical degree from Mount Sinai Medical Center in 1982. He then continued his medical and cardiovascular training at Mt. Sinai Medical Center.

Dr. Hershman has been an Invasive Cardiologist since 1987 and was involved in many clinical trials for emerging catheter technologies. He was a pioneer in performing laser-assisted coronary angioplasty, starting in private practice on Long Island in 1989. Presently the Medical Director of NYU Langone Long Island Cardiac Care he built and manages a large medical practice, employing cutting-edge technology and continues his practice for patients with cardiovascular and peripheral vascular diseases, employing a non-invasive therapy for patients with intractable Angina and Congestive Heart Failure.

Dr. Hershman has also been an entrepreneur and investor for more than two decades. He has been involved in life science investing and consulting for several years and previously or currently serves on the boards of medical biotechnology companies Solubest, Ltd., TheraVitae Inc., Nasus Pharma, SanoNash and Optivasive. He also serves as an advisor to a latestage, life science venture capital company that has funded 24 companies to-date. Dr. Hershman is now an investor in OurCrowd, Ltd., a leading crowd funding company and is the Co-Founder and CEO of HealthEffect, LLC and CLiHealth, LLC, SoLoyal and Nasus Pharma along with SanoNash.

Dr. Hershman continues to evaluate new medical technologies in the USA and Israel. His main interests lie in bringing improved medical technologies from the bench to the clinic, quickly and globally. He is actively seeking to commercialize technologies that improve lives and cure illnesses in the most effective and cost efficient manner.

Stem Cell therapies are the future in so many chronic illnesses and Hemostemix is an exciting company with a lot of promise in providing solutions and therapeutic options for many patients with critical Cardiovascular illnesses and ischemia, commented Dr. Hershman. As an investor and Board Member, I hope to assist in advancing these therapies further and create optimal value for patients and shareholders, alike, he said.

Dr. Hershman is replacing Mr. Yari Nieken and Mr. Bryson Goodwin who both resigned from their positions with the Company effective February 10, 2020. Ms. Natasha Sever has also resigned from the position of CFO. The Company will look for suitable replacements for both CEO and CFO positions and Mr. Smeenk will act as the interim CEO until a replacement is hired. The Company thanks Bryson, Yari and Natasha for their service and wishes them well in their future endeavors.

It is a great pleasure to welcome Dr. Hershman to the Board of Directors, said David Wood, Chairman, as he compliments us with his broad medical experience, biotechnology and business investment acumen and counsel.

I am honored and delighted to welcome Dr. Hershman to the Board of Directors and I very much look forward to his counsel, said Thomas Smeenk, President.

The Company also announces that on January 9, 2020, J.M. Wood Investment Inc. (JMWI) sent the Company a Notice of Default and Demand for the immediate repayment of the Companys previously announced convertible debenture and demand loan. Based on the repayment conditions of the debts, the Company took the position the January 9th notice was premature. On January 24th, JMWI made an application to the Court of Queens Bench of Alberta for the issuance of an order appointing a receiver. The Company responded with a 347 page affidavit including appendices, sworn on January 30th by David Wood, Chairman. The application was heard on January 31st by Madame Justice Horner, who granted a consent order to adjourn the JMWI receivership application to February 20, 2020 to enable the Company to close its financing; granted an order appointing Grant Thornton as inspector; granted an order that the costs of the application of January 31st would only be payable by the Company if the application proceeds on February 20th. On February 6, 2020 cross examinations on the Affidavits of David Wood and JMWI were heard.

Also, on February 3, 2020 the Company received an action from Aspire Health Science, LLC filed with the Ninth Judicial Circuit Court for Orange County, State of Florida, in connection with the Amended and Restated License Agreement rescinded by Hemostemix on December 5, 2019 due to Aspires failure to meet the Condition Precedent of paying US$1,000,000 within 30 business days of September 30, 2019. The Company believes the action is frivolous, without merit, and it intends to vigorously defend its position.

The Company intends to effect repayment of the secured debts and it will provide a further update to the market at that time. Although the Company is optimistic that it will be successful in raising sufficient funds to meet its obligations, there can be no assurance that the financing will close as anticipated or within the time frames required.

ABOUT HEMOSTEMIX INC.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other heart conditions. ACP-01 has been used to treat over 300 patients, including no-option end-stage heart disease patients, and it has been the subject of four open label phase II clinical studies which proved its safety and efficacy.

On October 21, 2019, the Company announced the results from its presentation from its Phase II CLI trial abstract presentation entitled Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years. The Companys clinical trial for CLI is ongoing at 20 clinical sites in North America and 56 of 95 subjects have been enrolled to-date.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact:

Thomas Smeenk, President & CEOSuite 1150, 707 7th Avenue S.W.Calgary, Alberta T2P 3H6Tel: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential, and similar expressions, or that events or conditions will, would, may, could, or should occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Companys ability to fund operations and access the capital required to continue operations and repay its secured debts, the Companys stage of development, the ability to complete its current CLI clinical trial, complete a futility analysis and the results of such, future clinical trials and results, long-term capital requirements and future developments in the Companys markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Companys operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Additional information identifying risks and uncertainties are contained in the Companys filing with the Canadian securities regulators, which filings are available at http://www.sedar.com.

Cancer patients use more blood than those fighting any other disease – Portsmouth Daily Times

By adminFebruary 11, 2020Stem Cell Medical Center

Patients fighting cancer need more blood than patients fighting any other disease, using nearly one-quarter of the nations blood supply. Thats why this February, the American Red Cross and the American Cancer Society have teamed up to encourage people across the country to Give Blood to Give Time, ensuring loved ones have the strength and support to battle cancer.

According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with cancer in their lifetime. An estimated 71,850 new cases of cancer will be diagnosed in Ohio this year; 71,850 in Ohio; 26,500 in Kentucky; and 12,380 in West Virginia. Many of these people will likely have a need for blood.

A loved ones cancer diagnosis often makes families and friends feel helpless. Thats why the Give Blood to Give Time partnership with the American Cancer Society is so important, said Dr. Pampee Young, chief medical officer, American Red Cross. When someone donates blood or platelets or makes a financial gift, they are helping to give patients and their families time, resources and the hope they need to fight back.

To schedule a blood or platelet donation appointment or make a financial gift, visit GiveBloodToGiveTime.org.

Some types of chemotherapy can damage bone marrow, reducing red blood cell and platelet production. Other times, the cancer itself or surgical procedures cause the problem. Blood products are often needed. In fact, five units of blood are needed every minute to help someone going through cancer treatment. Yet only 3% of people in the United States give blood. More people are needed to donate regularly to help meet the need.

The need for blood in cancer treatments is an important and untold story, said Gary Reedy, chief executive officer of the American Cancer Society. The American Cancer Society is excited to be working with the Red Cross on Give Blood to Give Time. Through this partnership, we want people to know there are multiple ways they can help and make a meaningful difference in the lives of patients and their families.

Individuals can honor their loved ones by making a blood donation appointment or financial contribution at GiveBloodToGiveTime.org.

Who blood donations help

In April 2015, Stephenie Perry was diagnosed with Hodgkin lymphoma exactly 10 days before her commencement ceremony from graduate school. One week after commencement, treatments began. During chemotherapy and two stem cell transplants, she needed blood and platelet transfusions.

I dont even know how many units of blood Ive received, she said. But I know all of that blood came from selfless individuals who made the decision to make an appointment and donate.

Last February, Perry received the good news that her cancer is in remission. The next day, her then-boyfriend, Justin Perry, proposed to her just in time for Valentines Day. They talked about marriage while she battled cancer, but they wanted to wait until she was in remission. Justin Perry said he didnt want to go another day without asking her to marry him. They were married in September.

Her red blood cell counts still get low at times. When that happens, she goes in for another blood transfusion.

I think its safe to say that my successful battle with cancer depended upon complete strangers and their donated blood. For this, I am grateful, Stephenie Perry said. Sometimes I hear stories from friends about people who are scared of needles or afraid to donate blood. I wish I could stand face-to-face with those people and tell them there is nothing scary about saving a life a life like mine.

Upcoming blood donation opportunities:

KENTUCKY

Boyd

Ashland

2/21/2020: 11:30 a.m. 5 p.m., Bellefonte Pavillion, 2000 Ashland Drive

_______________

Mason

Mayslick

2/21/2020: 3:30 p.m. 8 p.m., Mays Lick Community Center, 5036 salt lick circle

Maysville

2/13/2020: 1 p.m. 6 p.m., Church of the Nativity, 31 East Third St

_______________

Rowan

Morehead

2/11/2020: 12 p.m. 4:30 p.m., Carl D Perkins Community Center, Flemingsburg Rd

OHIO

Gallia

Gallipolis

2/12/2020: 11 a.m. 4 p.m., Holzer Gallipolis, 100 Jackson Pike

2/20/2020: 12:30 p.m. 6 p.m., Saint Peters Episcopal Church, 541 2nd Avenue

Jackson

2/18/2020: 12:30 p.m. 6 p.m., Christ United Methodist Church, 150 Portsmouth Street

2/20/2020: 1 p.m. 5:30 p.m., First Church of the Nazarene, 251 Powell Drive

Wellston

2/22/2020: 9 a.m. 3 p.m., LifeSource Apostolic Church, 110 Driving Park Rd

_______________

Lawrence

Ironton

2/20/2020: 10 a.m. 3:30 p.m., Ohio University Riffe Center, 1804 Liberty Avenue

2/27/2020: 8 a.m. 1:30 p.m., Rock Hill High School, 2415 County Road 26

Proctorville

2/18/2020: 9 a.m. 2:30 p.m., Fairland High School, 812 County Road 411

South Point

2/29/2020: 9 a.m. 2:30 p.m., Tri-State Worship Center, 901 Solida Road

_______________

Meigs

Pomeroy

2/19/2020: 1:30 p.m. 6 p.m., Mulberry Community Center, 260 Mulberry Ave

Reedsville

2/14/2020: 8 a.m. 1:30 p.m., Eastern Local High School, 38900 Ohio State Route 7

_______________

Scioto

Portsmouth

2/18/2020: 8:30 a.m. 1 p.m., Clay High School, 44 Clay High St.

2/25/2020: 12 p.m. 5:30 p.m., First Presbyterian Church, 3rd and Court Street, 221Court Street

WEST VIRGINIA

Boone

Madison

2/15/2020: 9 a.m. 1:30 p.m., Madison Fire Department, 1 Firehouse Square

Braxton

Gassaway

2/18/2020: 2 p.m. 6:30 p.m., Braxton County Memorial Hospital, 100 Hoylman Drive

_______________

Cabell

Huntington

2/10/2020: 10:30 a.m. 6:30 p.m., Huntington Donation Center, 1111 Veterans Memorial Blvd

2/13/2020: 1 p.m. 5 p.m., HIMG Regional Medical Ctr, 5170 US Rt 60 East

2/17/2020: 10:30 a.m. 6:30 p.m., Huntington Donation Center, 1111 Veterans Memorial Blvd

2/19/2020: 11 a.m. 4:30 p.m., St. Marys Center for Education, 2825 5th Avenue

2/24/2020: 10:30 a.m. 6:30 p.m., Huntington Donation Center, 1111 Veterans Memorial Blvd

_______________

Clay

2/25/2020: 8:30 a.m. 2 p.m., Clay County High School, 1 Panther Drive

_______________

Kanawha

Charleston

2/12/2020: 11 a.m. 5 p.m., University of Charleston, 2300 Maccorkle Ave

2/25/2020: 9 a.m. 3 p.m., Carver Career School, 4799 Midland Drive

Cross Lanes

2/14/2020: 2 p.m. 7 p.m., Cross Lanes YMCA Child Dev Ce, 5113 Rocky Fork Road

Dunbar

2/13/2020: 2 p.m. 7 p.m., Dunbar Church of the Nazarene, 1334 Lightener Auenue

Nitro

2/10/2020: 1 p.m. 5:30 p.m., Nitro Senior Center, 302 21st Street

Saint Albans

2/13/2020: 9 a.m. 2:30 p.m., First Baptist Church of St. Albans, 523 2nd St and 6th Ave

South Charleston

2/26/2020: 9 a.m. 2 p.m., Thomas Memorial Hospital, 4605 MacCorkle Avenue SW

_______________

Lincoln

Hamlin

2/26/2020: 9 a.m. 2:30 p.m., Lincoln County High School, 81 Panther Way

Logan

Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy…

By adminFebruary 11, 2020Stem Cell Medical Center

BOTHELL, Wash. and TOKYO, Feb. 10, 2020 /PRNewswire/ --Seattle Genetics, Inc.(Nasdaq: SGEN) and Astellas Pharma Inc.(TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced updated results from the phase 1b/2 clinical trial EV-103 in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy. Forty-five patients were treated with the combination of PADCEV (enfortumab vedotin-ejfv) and pembrolizumab and were evaluated for safety and efficacy. After a median follow-up of 11.5 months, the study results continue to meet outcome measures for safety and demonstrate encouraging clinical activity for this platinum-free combination in a first-line setting. Updated results will be presented during an oral session on Friday, February 14 at the 2020 Genitourinary Cancers Symposium in San Francisco (Abstract #441). Initial results from the study were presented at the European Society of Medical Oncology Congress in September 2019.

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.1,2

"Cisplatin-basedchemotherapy is the standard treatment for first-line advanced urothelial cancer; however, it isn't an option for many patients,"said Jonathan E. Rosenberg, M.D., Medical Oncologist and Chief, Genitourinary Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York."I'm encouraged by these interim results, including a median progression-free survival of a year for patients who received the platinum-free combination of PADCEV and pembrolizumab in the first-line setting."

In the study, 58 percent (26/45) of patients had a treatment-related adverse event greater than or equal to Grade 3: increase in lipase (18 percent; 8/45), rash (13 percent; 6/45), hyperglycemia (13 percent; 6/45) and peripheral neuropathy (4 percent; 2/45); these rates were similar to those observed with PADCEV monotherapy.3Eighteen percent (8/45) of patients had treatment-related immune-mediated adverse events of clinical interest greater than or equal to Grade 3 that required the use of systemic steroids (arthralgia, dermatitis bullous, pneumonitis, lipase increased, rash erythematous, rash maculo-papular, tubulointerstitial nephritis, myasthenia gravis). None of the adverse events of clinical interest were Grade 5 events. Six patients (13 percent) discontinued treatment due to treatment-related adverse events, most commonly peripheral sensory neuropathy. As previously reported, there was one death deemed to be treatment-related by the investigator attributed to multiple organ dysfunction syndrome.

The data demonstrated the combination of PADCEV plus pembrolizumab shrank tumors in the majority of patients, resulting in a confirmed objective response rate (ORR) of 73.3 percent (33/45; 95% Confidence Interval (CI): 58.1, 85.4) after a median follow-up of 11.5 months (range,0.7 to 19.2). Responses included 15.6 percent (7/45) of patients who had a complete response (CR)and 57.8 percent (26/45) of patients who had a partial response. Median duration of response has not yet been reached (range 1.2 to 12.9+ months). Eighteen (55%) of 33 responses were ongoing at the time of analysis, with 83.9% of responses lasting at least 6 months and 53.7% of responses lasting at least 12 months (Kaplan-Meier estimate).The median progression-free survival was 12.3 months (95% CI: 7.98, -) and the 12-month overall survival (OS) rate was 81.6 percent (95% CI: 62 to 91.8 percent); median OS has not been reached.

"These updated data are encouraging and provide support for the recently initiated phase 3 trial EV-302 that includes an arm evaluating PADCEV in this platinum-free combination in the first-line setting," said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.

"These additional results support continued evaluation of PADCEV in combination with other agents and at earlier stages of treatment for patients withurothelial cancer," said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head at Astellas.

About the EV-103 TrialEV-103 is an ongoing, multi-cohort, open-label, multicenter phase 1b/2 trial of PADCEV alone or in combination, evaluating safety, tolerability and efficacy in muscle invasive, locally advanced and first- and second-line metastatic urothelial cancer.

The dose-escalation cohort and expansion cohort A include locally advanced or metastatic urothelial cancer patients who are ineligible for cisplatin-based chemotherapy. Patients were dosed in a 21-day cycle, receiving an intravenous (IV) infusion of enfortumab vedotin on Days 1 and 8 and pembrolizumab on Day 1. At the time of this initial analysis, 45 patients (5 from the dose-escalation cohort and 40 from the dose-expansion cohort A) with locally advanced and/or metastatic urothelial cancer had been treated with enfortumab vedotin (1.25 mg/kg) plus pembrolizumab in the first-line setting.

The primary outcome measure of the cohorts included in this analysis is safety. Key secondary objectives related to efficacy include objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression free survival (PFS) and overall survival (OS). DoR,PFS and OS are not yet mature.

Additional cohorts in the EV-103 study will evaluate enfortumab vedotin:

More information about PADCEV clinical trials can be found at clinicaltrials.gov.

About Bladder and Urothelial CancerIt is estimated that approximately 81,000 people in the U.S. will be diagnosed with bladder cancer in 2020.5 Urothelial cancer accounts for 90 percent of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.6 Globally, approximately 549,000 people were diagnosed with bladder cancer in 2018, and there were approximately 200,000 deaths worldwide.7

The recommended first-line treatment for patients with advanced urothelial cancer is a cisplatin-based chemotherapy. For patients who are ineligible for cisplatin, such as people with kidney impairment, a carboplatin-based regimen is recommended. However, fewer than half of patients respond to carboplatin-based regimens and outcomes are typically poorer compared to cisplatin-based regimens.8

About PADCEV PADCEV (enfortumabvedotin-ejfv) was approved by the U.S. Food and Drug Administration (FDA) in December 2019 and is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting. PADCEV was approved under the FDA's Accelerated Approval Program based on tumor response rate. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.9

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.2,9Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).9PADCEV is co-developed by Astellas and Seattle Genetics.

Important Safety Information

Warnings and Precautions

Adverse ReactionsSerious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, and sepsis (each 0.8%).

Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%). Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).

The most common adverse reactions (20%) were fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%). The most common Grade 3 adverse reactions (5%) were rash (13%), diarrhea (6%) and fatigue (6%).

Lab AbnormalitiesIn one clinical trial, Grade 3-4 laboratory abnormalities reported in 5% were: lymphocytes decreased, hemoglobin decreased, phosphate decreased, lipase increased, sodium decreased, glucose increased, urate increased, neutrophils decreased.

Drug Interactions

Specific Populations

For more information, please see the full Prescribing Information for PADCEV here.

About Seattle GeneticsSeattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people's lives. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit https://www.seattlegenetics.comand follow @SeattleGenetics on Twitter.

About AstellasAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en.

About the Astellas and Seattle Genetics CollaborationSeattle Genetics and Astellas are co-developing enfortumab vedotin-ejfv under a collaboration that was entered into in 2007 and expanded in 2009. Under the collaboration, the companies are sharing costs and profits on a 50:50 basis worldwide.

Seattle Genetics Forward-Looking StatementsCertain statements made in this press release are forward looking, such as those, among others, relating to the EV-103 and EV-302 clinical trials; clinical development plans relating to enfortumab vedotin; the therapeutic potential of enfortumab vedotin; and its possible safety, efficacy, and therapeutic uses, including in the first-line setting. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the possibility that ongoing and subsequent clinical trials of enfortumab vedotin may fail to establish sufficient efficacy; that adverse events or safety signals may occur and that adverse regulatory actions or other setbacks could occur as enfortumab vedotin advances in clinical trials even after promising results in earlier clinical trials. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption "Risk Factors" included in the company's Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Astellas Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

1 PADCEV [package insert]. Northbrook, IL: Astellas, Inc.2 Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.3 Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2019;37(29):2592-600.4 ClinicalTrials.gov. A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103). https://clinicaltrials.gov/ct2/show/NCT03288545.5 American Cancer Society. Cancer Facts & Figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed 01-23-2020.6National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 05-01-2019.7International Agency for Research on Cancer. Cancer Tomorrow: Bladder. http://gco.iarc.fr/tomorrow. 8 National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 4; July 10, 2019. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.9 PADCEV [package insert]. Northbrook, IL: Astellas, Inc.

SOURCE Astellas

http://www.seattlegenetics.com

See the article here:
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy...

Sinai and Synapses names new class of 15 fellows – Covalence

By adminFebruary 11, 2020Stem Cell Medical Center

The latest incoming class of fellows for the Sinai and Synapses Fellowship now includes a computer science professor, a spiritual care coordinator, biology professor, rabbi and an ethicist.

This 15-strong group will be seeking out models for productive conversation surrounding religion and science through 2021 and were just named by the group founded by Rabbi Geoffrey A. Mitelman, who is incubating the group at Clal The National Jewish Center for Learning and Leadership.

The fellowship, however, is interfaith and is designed to encourage curiosity and the creation of new questions to explore in religion and science. According to the groups website, the fellows engage in their own communities and create meaningful content that includes podcasts such as: Down the Wormhole and More Light, Less Heat series.

One of this years fellows, Kristel Clayville, plans to work on something public-facing possibly in the form of a podcast focused on religion, science and technology. Clayville is the acting director of the Zygon Center for Religion and Science at the Lutheran School of Theology at Chicago, as well as a senior fellow at the MacLean Center for Clinical Medical Ethics at the University of Chicago. She currently works as a chaplain and ethicist at the University of Chicago Medical Center and focuses on the existential and spiritual issues facing organ transplant patients. She has also done work at the intersection between environmental ethics and bioethics to study the green burial movement.

Here are the rest of this years fellows and some of the experience they bring to the fellowship:

Editor

Susan is an author with a long-time interest in religion and science. She currently edits Covalence, the Lutheran Alliance for Faith, Science and Technologys online magazine. She has written articles in The Lutheran and the Zygon Center for Religion and Science newsletter. Susan is a board member for the Center for Advanced Study of Religion and Science, the supporting organization for the Zygon Center and the Zygon Journal. She also co-wrote Our Bodies Are Selves with Dr. Philip Hefner and Dr. Ann Pederson.

Mystery of Leaky Gut Plumbed by UCSD Team, Which Created Mini-Guts – Times of San Diego

By adminFebruary 11, 2020Stem Cell Clinics

Share This Article:A mini-gut organoid generated in the lab from human stem cells. Photo via ucsdnews.ucsd.edu

A team of UC San Diego School of Medicine researchers created a miniature gut in a lab to simulate and pinpoint the causes of a mysterious malady known as leaky gut, the school announced Monday.

Support Times of San Diego's growthwith a small monthly contribution

The condition occurs frequently in older patients, those with cancer or chronic illnesses and those with stressful lifestyles.

Essentially, the lining of intestines becomes more permeable, allowing bacteria and microbes to pass through the gut and contribute to diseases driven by chronic inflammation, such as inflammatory bowel disease, dementia, atherosclerosis and liver fibrosis, among others.

UCSD officials said it is difficult for physicians to tell who has leaky gut, and there are no treatments for it.

By taking biopsies from patients, researchers were able to take stem cells to create 3D models of human intestines to study the ailment. The organoids, or mini-guts, tell the story of the condition including revealing biomarkers which doctors could eventually use to diagnose and treat the condition, school officials said.

Dr. Pradipta Ghosh, professor of cellular and molecular medicine at UCSD School of Medicine and Moores Cancer Center, was first author of the report published in Life Science Alliance. Dr. Soumita Das, associate professor of pathology at UCSD School of Medicine, was the senior author.

According to the researchers, they rolled open the mini-gut balls to expose the surface of the intestinal lining. They then sprinkled on several types of bacteria, which stressed the gut lining junctions and caused them to fall apart. Those junctions between gut cells break down with aging and in the presence of colorectal tumors.

Each model gut differed from patient to patient, which Ghosh said was helpful to the research but also imposed limits.

Lots of research is done in mice that are inbred so that they are genetically identical, all in the same cage, eating the same diet, in order to remove these variables from the studies, she said. But lab mice are far more standardized than the same human from day to day, or patients we see in the clinics. Here, our model is a better representation of humanity. On the other hand, it also means that each organoid is its own unique experiment. We have to test many organoids to be able to make any claim, which we did in our study.

The researchers found that diabetes drug metformin activates an enzyme which helps tighten the cell junctions back up a potentially effective treatment for the condition.

The next step will be to look at diseases driven by leaky gut and to test various ways to tighten up those cell junctions.

I think youd be hard pressed to find a disease in which systemic inflammation is not a driver, Das said. Thats why, even though there are so many things we still dont know, were excited about the broad potential this model and these findings open for developing personalized leaky gut therapeutics.

To further advance these studies and others like it, Ghosh and Das lead HUMANOID, a core facility based at UCSD School of Medicine where researchers can access a number of different human organoids, including healthy or Alzheimers disease mini-brains and healthy or inflammatory bowel disease mini-guts, from both male and female patients at a variety of ages.

City News Service

Mystery of Leaky Gut Plumbed by UCSD Team, Which Created Mini-Guts was last modified: February 10th, 2020 by Ken Stone

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Glantz: Taking the ‘bad man’ test | Local News – The Times Herald

By adminFebruary 10, 2020Stell Cell Research

The official definition of the witching hour is when witches -- or magicians, ghouls, Republican senators and other demons -- are said be at their most powerful.

Thats the myth, the folklore.

The reality is that the witching hour is when we wake up in the middle of the night and our minds are clear enough to be haunted by our own bitter realities.

Unanswerable questions, many about futures we cant control, ravage the brain.

I was hit with one so immediate this past week that not even my home remedy sneaking downstairs for some old Sopranos episodes could make it right.

The question was this: Am I a bad person?

Here are three examples, hot off the presses, that had me wondering:

Andy Reid Much of Eagles Nation has forgiven and forgotten the specifics of the Reid Era here. They instead focus on the general success between 1999 and 2012.

But not me. I remember high hopes repeatedly dashed, and the seasons that ended in despair.

I invested too much in time, emotion and money (season ticket holder) -- to be stranded at the altar again and again and again.

Maybe some forget the feeling of having their hearts eaten out that were then met with the subsequent kick in our collective gut when Reid would act smug and indifferent during postgame press conferences.

Even when mishaps (dropped passes, missed tackles) werent directly his fault, Reids standard line was it begins with me.

Fine, Andy, you wanted the blame, you got it. I would have told you so if they let me to drive you to the airport when you left town.

Why, then, would I or anyone else who bleeds green root for Reid to have success elsewhere?

There was no worse scenario than his new team, the Kansas City Chiefs, winning a Super Bowl when he didnt do it in Philly after all those years of knocking on the door without finding a way to kick it in.

When we finally got it done two years ago, some of the edge was taken off. Still, when the Chiefs reached the big dance this year, I became a temporary fan of the opposing San Francisco 49ers.

Truth be told, I am more than a little bit angry with the end result (particularly the touchdown that wasnt a touchdown) and irked by all the glad tidings for Reid around the Delaware Valley.

Bad person?

Self-vote: Yeah, sigh, I am. Its not like he tried to lose big games here (it just seemed like it).

Iowa Caucuses I have been a detractor of the overall primary system for a long time, and my criticism begins with the disproportionate role little Iowa plays in the process.

I wrote all about it in my Sunday column a month or two ago, but I never could have imagined the Monday meltdown that will leave the final tally with an asterisk.

The root cause of the chaos was the already silly caucus process being further complicated with some second-round scenario that was clearly over the heads of those Iowa straw-chewers to comprehend.

While the good news is that this is probably the last we will see of the Iowa Caucuses, and maybe even Iowa getting to bat leadoff and set the pace as it has been doing, despite clearly not being a gauge of Americas diversity (its well over 90 percent lilywhite, for example) the embarrassment for the Democratic party could prove to be colossal.

Bad person?

Self-vote: Nope, not at all. A little bit of vindication is good for the soul.

Rush Limbaugh The right-wing AM Talk Radio host revealed that he is terminally ill.

If you are waiting for tears, keeping waiting.

I understand the man may have had a job to do, sort of in the Howard Stern shock jock sense, and that he may or may not have even meant half the hateful things he was saying.

But listeners many with pea brains accepted his postulating as fact.

And he knew it.

And he kept on spewing his garbage -- ironically losing his own hearing, so he couldnt even hear himself anymore.

If we are truly mired in a modern day Civil War, one in which lives (i.e. Heather Heyer) have been lost, Limbaugh is a general in the militia that fired the first shots (albeit away from the fray while on his bully pulpit).

It could be said that there would have been no coming of your president (not mine), without Limbaugh among others laying the groundwork.

No wonder Limbaugh got the Presidential Medal of Freedom the other night.

Hard to believe, though, considering this is the same person who called Iraq War veterans subsequently opposed to the war phony soldiers.

Then again, this prize was given to him by the phoniest of soldiers, one who got out of Vietnam with phantom bone spurs.

Like your president (not mine), Limbaugh built his empire on lies and half-truths.

Consider that Polifact rated Limbaughs on-air statements as either mostly false or pants on fire at a rapid-fire rate of 84 percent, with only a mere 5 percent registering as true.

While a lot of his false statements are about climate change, we are also talking about someone who continually degraded President Barack Obama with racially charged innuendoes calling him (and Oprah Winfrey) uppity, etc. and who compared NFL games to showdowns between black gangs.

He also said actor Michael J. Fox was exaggerating his Parkinsons disease in an ad for stem cell research.

I wonder if hed like some of that stem cell research for himself now? Maybe he is just exaggerating his symptoms.

Take the high road? Not this so-called snowflake. Its all low road here in Gordonville.

Bad person?

Self-vote: Abstain.

Originally posted here:
Glantz: Taking the 'bad man' test | Local News - The Times Herald

Stanford loses emotional game in Boulder, 81-74 – Rule Of Tree

By adminFebruary 10, 2020Stell Cell Research

Basketball, like life, sometimes isnt fair.

Covering Stanford, Ive had the pleasure of speaking with Oscar da Silva over the past few years. Its been well-publicized that he can speak six languages, and that hes serious about his classes, and that he conducts stem cell research. But theres so much more to him.

His game ended early today, and it was scary. As he hustled back to prevent a fast break bucket, charging full speed ahead was Colorados Evan Battey, one of the beefier forwards in the conference. The two collided around the restricted area, and as they flew to the ground, Batteys forearm forcibly slammed da Silvas head into the hardwood. It was inadvertent, but you could immediately tell it was serious. Oscar left the game on a stretcher.

You should hear the way that his teammates talk about him, or even see the way they look at him. When Jaiden Delaire flourished earlier in the year, he spoke about the impact Oscars had on him. It wasnt about how hes learned his moves or picked up a trick or two. Rather, he spoke about the tone that Oscar sets every day with his work-ethic and the way that he carries himself. Jerod Haase didnt have any captain last year, so bestowing that title on da Silva and Daejon Davis this year is a serious honor. Theyre like big brothers to their teammates.

This team has a deep bond. Jerod Haase is the father figure, who on multiple occasions has been on the verge of tears talking about how much he cares for his guys. The whole squad and staff visited Oscars hometown of Munich, mingling with his parents and younger brother in the Bavarian capital. Oscar spoke about how special it was to have his two worlds intersect like that, and all involved had a great experience.

Its hard to play a game after something like that happens to someone you care about so much. The two teams locked arms at half court during the stoppage, and players handled it in various ways. Daejon Davis had to sit on the bench in the immediate aftermath. Battey was distraught, approaching Haase in tears to apologize.

This was always going to be a difficult game for Stanford. They havent won in Boulder since 2012, and the Buffs are one of the conferences best teams this year. With Bryce Wills still nursing his injury from Thursday, a short Stanford rotation got even shorter. They even had to go to Sam Beskind, a former walk-on. But for some 30 minutes, none of that appeared to matter.

Stanford built an 11 point halftime advantage through superb play defensively, even without the conferences best defender. After Colorado hit their first shot of the game, they subsequently went on a 7+ minute field goal drought. Nothing came easy for them. They finished the first half shooting 28% from the field and 23% from deep.

The final moments of the opening period were wacky. Up by six points and with the clock ticking down, Tyrell Terry threw up a three point shot and appeared to kick his leg out. The ref whistled Colorado for a foul, and Colorado coach Tad Boyles justifiable anger earned him a technical. Terry hit all 5 foul shots.

The lead grew to as many as 16 in the second half. Much of this came more on the backs of unusual suspects like Jaiden Delaire and Isaac White, as da Silva and Davis were hampered with foul trouble. At the time of da Silvas injury, Stanford led 41-30 with some 16 minutes on the clock. The lead wouldnt be enough.

It wasnt like they didnt battle, because they definitely had fight in them. But they didnt have the same edge. Their defense that was so good in the first half suddenly found itself getting picked apart. Colorado made all 8 of their three point attempts after halftime, and that just proved to be too much for the short-handed and heavy-hearted Cardinal.

Their toughness is one positive takeaway, but not the lone one. After a couple months of shaky play and even drawing a healthy scratch, Jaiden Delaire showed out in a big way. The sophomore forward scored 19 points off the bench in a variety of ways, including 2 triples. When hes confident, Stanford is on another level. Isaac White added 4 threes himself off the pine. Even Beskind, who seldom sees action, seemed to blend in well enough.

Last year, Oscar had a bit of a slump during the non-conference stretch. He broke out of it in a big way in mid-December, and Daejon was there to provide an explanation: finals. Oscar had spread himself thin, taking a number of classes with challenging exams. His mind had been on biology and chemistry as much as it had been on basketball. da Silva grinned, as he never would have admitted such a thing. The whole scene was refreshing. Much in the vein of an Andrew Luck or Bryce Love, hes the ideal of a Stanford student-athlete.

Hopefully, this was all just a scare and Oscar will simply need time to rest up and recuperate. Per Stanford basketball, his head laceration required stitches, but were still waiting on the results from the concussion protocol. Either way, the outcome of this game doesnt at all feel like the most important thing today.

Follow this link:
Stanford loses emotional game in Boulder, 81-74 - Rule Of Tree

Hanging Medal On Limbaugh, Trump Honors Overt Hate Speech – The National Memo

By adminFebruary 10, 2020Stell Cell Research

Rush Limbaugh is a demagogue, an incendiary and malevolent media figure who traffics in the worst of racism and misogyny, coarsens the civic discourse and mainstreams baseless conspiracy theories. Borrowing the playbook of a 1930s Catholic priest whose radio show reveled in anti-Semitism and fascism, Limbaugh is the Father Coughlin of our age. His radio show is vile.

On Tuesday, President Donald J. Trump awarded Limbaugh the Presidential Medal of Freedom, which had previously been reserved for people whose lives and work lifted the nation people such as Rosa Parks, Jonas Salk and Walter Cronkite. By awarding it to Limbaugh, the president has saluted a bigot and enshrined his ideology as a national treasure.

Many political scientists and news media pundits would still like to believe that the Trump presidency rests largely on economic upheaval, on the sense of dislocation and alienation in working-class regions that have seen well-paying jobs lost to globalization and automation. And there is, no doubt, a despair in those regions that can be traced to the loss of financial security. But those workers are too easily persuaded that their plight is the fault of Mexicans and Muslims, that their jobs went to unqualified black or brown laborers.

And Limbaugh is their media hero, a man whose decades on the radio moved his dedicated followers to call themselves Dittoheads. And what inspired commentary sends them into such rapturous agreement? Heres one Limbaugh nugget: I think its time to get rid of this whole National Basketball Association. Call it the TBA, the Thug Basketball Association, and stop calling them teams. Call em gangs. Heres another: Have you ever noticed how all composite pictures of wanted criminals resemble Jesse Jackson?

The presidency of Barack Obama sent Limbaugh into reactionary overdrive; he was a committed birther, and he derided any Obama policy that expanded government benefits even when most of the beneficiaries were white as reparations. In one rant during Obamas first term, Limbaugh claimed that Obamas presidency represented the opportunity for people of color to use their power as a means of retribution. Thats what Obamas about. Hes angry, hes gon cut this country down to size, hes gon make it pay for its mistreatment of minorities.

Limbaugh also has full reservoirs of misogyny with which to drench women who dare seek equal treatment under the law. When a Georgetown University student named Sandra Fluke testified before Congress, seeking to have health insurance cover contraceptives, Limbaugh went on a vicious tear, denouncing her as a slut and a prostitute. He made the term feminazi a mainstream slur describing any woman who believes that she should have full citizenship. Feminism, he once declared, was established so as to allow unattractive women easier access to the mainstream of society.

To round out his repertoire of abhorrent and baseless attacks, he once mocked the actor Michael J. Fox, who suffers from Parkinsons disease, on the air, accusing him of exaggerating his symptoms. Fox had made a political ad in support of stem cell research, which scientists said might lead to a cure for Parkinsons, and viewers could see his pronounced tremors. He is moving all around and shaking, and its purely an act, Limbaugh insisted.

Of course, all that bigotry and bullying made him the perfect recipient of an award from Trump, who has channeled the same base impulses to power his way to the presidency. Indeed, Limbaugh helped pave the way for Trump. The talk radio meister made insults, cheap provocations and racist assaults on people of color commonplace even entertaining for a certain voting bloc. They were ready to welcome the bombastic reality TV host.

When Trump entered the political arena as a birther insisting that Obama was not born in the United States and was therefore illegitimate his base was already primed for it. When Trump was caught on audio tape bragging that he had sexually assaulted women, Limbaugh had already laid the groundwork for a presidency dismissive of common decency.

By awarding Limbaugh the Presidential Medal of Freedom, Trump has not succeeded in cheapening the award. Its distinctions will endure. But he has elevated Limbaughs racism, misogyny and free-floating malevolence, enshrining them as centerpieces of his presidency.

BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update – Yahoo Finance

By adminFebruary 10, 2020Stem Cell Treatment

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and full year ended December 31, 2019, and provide a corporate update, at 8:00 a.m., Eastern Time, on Tuesday, February 18, 2020.

BrainStorms President & CEO, Chaim Lebovits, will present the full year 2019 corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, and Preetam Shah, PhD, Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.comand questions should be submitted by 5:00 p.m., Eastern Time, Monday, February 17 2020.

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. Brainstorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. Brainstorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Story continues

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: 862-397-8160pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Here is the original post:
BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update - Yahoo Finance

Regenerative Medicine Market Analysis By Product Type, Therapeutic Category, Region And Forecast Till 2025 : Grand View Research Inc. – MENAFN.COM

By adminFebruary 10, 2020Stem Cell Treatment

(MENAFN - GetNews) According to report published by Grand View Research, The global regenerative medicine market size was estimated at USD 2.60 million in 2018 and is expected to witness a CAGR of 11.6% throughout the forecast period.

The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period, according to a new report by Grand View Research, Inc. Regenerative medicines are expected to have a significant impact in healthcare to treat specific indications and chronic conditions. Therefore, high prevalence of cancer, neurodegenerative, orthopedic, and other aging-associated disorders coupled with increasing global geriatric population is driving the market growth. Moreover, rising prevalence of inheritable genetic diseases is anticipated to fuel the demand in the field of biotechnology field.

Market players are engaged in implementing novel protocols for the release of novel therapeutics. For instance, in July 2018, Convelo Therapeutics launched regenerative medicines for the treatment of various neurological diseases, such as multiple sclerosis.Agreements models initiated by the companies coupled with commercialization in emerging countries fuels the growth. For instance, in March 2018, Hitachi Chemical signed an agreement with the Daiichi Sankyo and SanBio Group to conduct clinical manufacturing of regenerative medicines developed by respective companies for Japanese and U.S. markets.

Regenerative medicine is anticipated to witness great attention in healthcare sector due to its wide range of applications and significant advancements tissue engineering, stem cells, gene therapy, drug discovery, and nanotechnology. For example, 3D printing is preferred over scaffold with stem cells to restore structure and functional characteristics of biological specimens.

Dermatology is estimated to hold the largest market share in terms of revenue in 2018, owing to the availability of various products and their application in simple and chronic wound healing. Oncology therapeutic category on the other hand, is projected to expand at the fastest CAGR during the forecast period owing to the presence of strong pipeline of regenerative medicines for cancer treatment.

North America held the largest regenerative medicine market share in terms of revenue in 2018 and is projected to continue its dominance in near future. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in U.S. is anticipated to propel the growth.

Request a sample Copy of the Regenerative Medicine Market Research Report @ https://www.grandviewresearch.com/industry-analysis/regenerative-medicine-market/request/rs1

Key Takeaways Of The Report :

Therapeutics emerged dominant among product segments in 2018 due to high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies

Implementation of primary cell-based therapies in dermatological, musculoskeletal, and dental application results in highest share of this segment

Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in stem cell research and increasing number of stem cell banks

With rise in R & D and clinical trials, key players are offering consulting services leading to lucrative growth of the services segment

Asia Pacific is projected to witness the fastest CAGR during the forecast period due to rapid adoption of cell-based approaches in healthcare and emergence of key players

Key players operating in the regenerative medicine market including AstraZeneca; F Hoffmann-La Roche Ltd.; Pfizer Inc.; Merck & Co., Inc.; Integra LifeSciences Corporation; and Eli Lilly and Company

Have Any Query? Ask Our Experts @ https://www.grandviewresearch.com/inquiry/4557/ibb

Grand View Research has segmented the global regenerative medicine market on the basis of product type, therapeutic category, and region:

Regenerative Medicine Product Type Outlook (Revenue, USD Million, 2014 - 2025)

Therapeutics & Devices

Primary Cell-bases Therapeutics

Dermatology

Musculoskeletal

Surgical

Dental

Others

Stem Cell & Progenitor Cell-based Therapeutics

Autologous

Allogeneic

Others

Cell-based Immunotherapies

Gene Therapies

Tools

Banks

Services

Regenerative Medicine Therapeutic Category Outlook (Revenue, USD Million, 2014 - 2025)

Regenerative Medicine Regional Outlook (Revenue, USD Million, 2014 - 2025)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Browse Related Reports:

Biopreservation Market : https://www.grandviewresearch.com/industry-analysis/biopreservation-market

Molecular Cytogenetics Market : https://www.grandviewresearch.com/industry-analysis/molecular-cytogenetics-market

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

Media Contact Company Name: Grand View Research, Inc. Contact Person: Sherry James, Corporate Sales Specialist - U.S.A. Email: Send Email Phone: 1-415-349-0058, Toll Free: 1-888-202-9519 Address: 201, Spear Street, 1100 City: San Francisco State: California Country: United States Website: https://www.grandviewresearch.com/industry-analysis/regenerative-medicine-market

MENAFN1002202000703268ID1099679792

See the article here:
Regenerative Medicine Market Analysis By Product Type, Therapeutic Category, Region And Forecast Till 2025 : Grand View Research Inc. - MENAFN.COM